scholarly journals The Safe Baculovirus-Based PrM/E DNA Vaccine Protected Fetuses Against Zika Virus in A129 Mice

Vaccines ◽  
2021 ◽  
Vol 9 (5) ◽  
pp. 438
Author(s):  
 Hanul Choi ◽  
Jungmin Chun ◽  
Mina Park ◽  
Suyeon Kim ◽  
Nahyun Kim ◽  
...  
Keyword(s):  
Zika Virus ◽  
Neutralizing Antibodies ◽  
Recombinant Baculovirus ◽  
Endogenous Retrovirus ◽  
Human Endogenous Retrovirus ◽  
Knock Out ◽  
Baculovirus Vector ◽  
Genetic Vaccine ◽  
Potential Vaccine ◽  
Knock Out Mice

The Zika virus (ZIKV) is a mosquito-borne member of the Flaviviridae family of enveloped RNA viruses. The correlation between viral infection and fetal microcephaly was revealed in 2015, yet we still lack a vaccine against ZIKV. Here, we present a genetic vaccine that delivers the premembrane (prM) and envelope (E) genes of ZIKV using a recombinant baculovirus vector that expresses a human endogenous retrovirus (HERV) envelope on its surface to enhance gene delivery. We observed that baculoviruses with HERV envelopes (AcHERV) exhibited specifically higher gene transfer efficiency in human cells compared to the wild-type baculovirus vector. Using the AcHERV baculovirus vector, we constructed a recombinant baculovirus vaccine encoding ZIKV prM/E genes (AcHERV-ZIKV), which are major targets of neutralizing antibodies. Mice immunized twice with AcHERV-ZIKV exhibited high levels of IgG, neutralizing antibodies, and IFN-γ. In challenge tests in IFN knock-out mice (A129), AcHERV-ZIKV showed complete protection in both challenge and pregnancy tests. These results suggest that AcHERV-ZIKV could be a potential vaccine candidate for human application.

scholarly journals Development of Zika Virus DNA Vaccine Using Envelope Modified Baculoviral Gene Delivery System

Proceedings ◽  
2020 ◽  
Vol 50 (1) ◽  
pp. 85
Author(s):  
Hanul Choi ◽  
Yuyeon Jang ◽  
Hansam Cho ◽  
Ha Youn Shin ◽  
Young Bong Kim
Keyword(s):  
Gene Delivery ◽  
Dna Vaccine ◽  
Zika Virus ◽  
Neutralizing Antibodies ◽  
Challenge Test ◽  
Recombinant Baculovirus ◽  
Endogenous Retrovirus ◽  
Human Endogenous Retrovirus ◽  
Cmv Promoter ◽  
Wide Range

Zika virus (ZIKV) is a mosquito-borne flavivirus and the infection of pregnant women can cause a wide range of congenital abnormalities, including microcephaly in the infant. However, there is no vaccine available yet. In this study, we intended to use PrM/E, which is the main target gene of neutralizing antibodies, for the development of a DNA vaccine for ZIKV. To enhance the gene delivery, a recombinant baculovirus whose surface was modified to express human endogenous retrovirus (HERV) envelope was constructed. Baculovirus with HERV envelope (AcHERV) showed distinguished higher gene delivery than wild type. Using the AcHERV as a delivery vector, we constructed major antigen (prM-E)-encoding DNA under the CMV promoter, AcHERV–ZIKA. Transducing of prM/E gene in a mammalian cell was confirmed by Western blot. Immunization in mice with 10e7 of AcHERV–ZIKA elicited high IgG and neutralizing antibodies. In the challenge test, AcHERV–ZIKA immunized A129 mice showed perfect protection. These results suggest that AcHERV–ZIKA could be a potential vaccine candidate for human application.

Knock-out of the human endogenous retrovirus ERV3 using CRISPR/Cas9 technology

Placenta ◽  
2016 ◽  
Vol 45 ◽  
pp. 107-108
Author(s):  
Hanna Huebner ◽  
Fabian B. Fahlbusch ◽  
Arif B. Ekici ◽  
Georgia Vasileiou ◽  
Matthias W. Beckmann ◽  
...  
Keyword(s):  
Endogenous Retrovirus ◽  
Human Endogenous Retrovirus ◽  
Knock Out

scholarly journals Lethal Zika Virus Disease Models in Young and Older Interferon α/β Receptor Knock Out Mice

2018 ◽  
Vol 8 ◽  
Author(s):  
Andrea Marzi ◽  
Jackson Emanuel ◽  
Julie Callison ◽  
Kristin L. McNally ◽  
Nicolette Arndt ◽  
...  
Keyword(s):  
Zika Virus ◽  
Virus Disease ◽  
Disease Models ◽  
Interferon Α ◽  
Knock Out ◽  
Β Receptor ◽  
Knock Out Mice

scholarly journals Human endogenous retrovirus-enveloped baculoviral DNA vaccines against MERS-CoV and SARS-CoV2

npj Vaccines ◽  
2021 ◽  
Vol 6 (1) ◽  
Author(s):  
Hansam Cho ◽  
Yuyeon Jang ◽  
Ki-Hoon Park ◽  
Hanul Choi ◽  
Aleksandra Nowakowska ◽  
...  
Keyword(s):  
Dna Vaccine ◽  
Viral Infections ◽  
Dna Vaccines ◽  
Recombinant Baculovirus ◽  
Endogenous Retrovirus ◽  
Human Endogenous Retrovirus ◽  
Cell Mediated Immunity ◽  
Envelope Gene ◽  
Dna Encoding ◽  
Challenge Tests

AbstractHere we report a recombinant baculoviral vector-based DNA vaccine system against Middle East respiratory syndrome coronavirus (MERS-CoV) and the severe acute respiratory syndrome coronavirus-2 (SARS-CoV2). A non-replicating recombinant baculovirus expressing the human endogenous retrovirus envelope gene (AcHERV) was constructed as a DNA vaccine vector for gene delivery into human cells. For MERS-CoV vaccine construction, DNA encoding MERS-CoV S-full, S1 subunit, or receptor-binding domain (RBD) was inserted into the genome of AcHERV. For COVID19 vaccine construction, DNA encoding SARS-CoV2 S-full or S1 or a MERS-CoV NTD domain-fused SARS-CoV2 RBD was inserted into the genome of AcHERV. AcHERV-DNA vaccines induce high humoral and cell-mediated immunity in animal models. In challenge tests, twice immunized AcHERV-MERS-S1 and AcHERV-COVID19-S showed complete protection against MERS-CoV and SARS-CoV2, respectively. Unlike AcHERV-MERS vaccines, AcHERV-COVID19-S provided the greatest protection against SARS-CoV2 challenge. These results support the feasibility of AcHERV-MERS or AcHERV-COVID19 vaccines in preventing pandemic spreads of viral infections.

Sign in / Sign up

Export Citation Format

Share Document